Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by SELLAS Life Sciences Group, Inc. on June 16, 2026. The meeting addressed five proposals regarding board composition, auditor ratification, equity plan amendments, executive compensation, and meeting adjournment procedures.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Approximately 62.59% of outstanding shares (115,511,771 shares) were present or represented by proxy. The following material actions were taken:
- Board Election (Proposal 1): Stockholders re-elected Robert Van Nostrand and Jane Wasman as Class I directors. Both nominees received majority support, though significant broker non-votes (44,477,593) were recorded.
- Auditor Ratification (Proposal 2): Stockholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Equity Plan Amendment (Proposal 3): Stockholders approved an amendment to the 2023 Amended and Restated Equity Incentive Plan to increase the number of shares available for issuance by 20,000,000. This proposal faced notable opposition, with 27,310,386 votes cast against.
- Executive Compensation (Proposal 4): Stockholders approved the non-binding advisory resolution on executive compensation. Similar to the equity plan, this proposal received 15,906,732 votes against.
- Adjournment (Proposal 5): Stockholders approved the authority to adjourn the meeting to solicit additional proxies if necessary.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. The document is strictly limited to the reporting of voting outcomes.
Investor Verification Checklist
- Verify the impact of the 20,000,000 share increase in the 2023 Equity Plan on potential future dilution.
- Review the significant number of broker non-votes (44,477,593) recorded for Proposals 1, 3, and 4 to understand shareholder engagement levels.
- Confirm the transition of the independent auditor from Moss Adams LLP to Baker Tilly US, LLP for the 2026 fiscal year.
- Monitor future filings for the company's financial performance, as this 8-K contains no financial data.